Targeted Peptide Therapy // IVUSE+

PT-141

PT-141. A melanocortin agonist that activates desire at its neurological origin. FDA-approved as Vyleesi. Not a vasodilator. A signal to want.

10MG/ML

Sexual Desire Enhancement Central Arousal Activation Neurogenic Erectile Support On-Demand Dosing

Clinician-prescribed. Ships from a licensed U.S. pharmacy.

The Mechanism

Desire Starts in the Brain. Not the Blood.

PDE5 inhibitors (Viagra, Cialis) increase blood flow. They address the hydraulics of erection without touching the motivation to want. PT-141 works upstream, in the hypothalamus, where melanocortin receptors MC3R and MC4R govern the neural architecture of sexual desire. When PT-141 binds these receptors, it triggers dopamine release in reward circuits and oxytocin stimulation from the paraventricular nucleus. The result is the subjective experience of wanting. Not forced arousal. Not mechanical response. The drive to seek, to initiate, to want what your body had stopped asking for. This is why PT-141 works for both men and women: desire is neurological, not genital.

Clinical Data

The Evidence

FDA

Approved 2019 as Vyleesi for hypoactive sexual desire disorder

MC4R

Hypothalamic melanocortin receptor mediating central desire activation

CNS

First FDA-approved treatment acting through central nervous system for sexual desire

FDA Label, Vyleesi (bremelanotide), 2019

Comparison

Conventional Sexual Dysfunction Treatments vs. PT-141 (Bremelanotide)

Conventional Sexual Dysfunction Treatments	PT-141 (Bremelanotide)
PDE5 inhibitors address blood flow without affecting desire or motivation	Activates desire at hypothalamic MC3R/MC4R, the neurological origin of wanting
Testosterone therapy requires ongoing hormonal manipulation and monitoring	On-demand dosing, no daily regimen or hormonal manipulation required
Flibanserin (Addyi) requires daily dosing with alcohol restrictions	FDA-approved specifically for hypoactive sexual desire disorder
Psychotherapy addresses cognitive patterns but not neurochemical drive	Works for both men and women because desire is neurological, not genital
Supplements lack clinical evidence for desire-specific mechanisms	Triggers dopamine and oxytocin release in desire-specific brain regions
Each addresses one layer without targeting the central desire circuit	Complementary to PDE5 inhibitors: desire (PT-141) plus mechanics (sildenafil)

Product Information

Details

PT-141 (Bremelanotide) is a synthetic cyclic heptapeptide derived from Melanotan II. FDA-approved in 2019 as Vyleesi for hypoactive sexual desire disorder in premenopausal women. It is the first and only FDA-approved treatment targeting sexual desire through the central nervous system rather than peripheral vascular mechanisms. PT-141 binds MC3R and MC4R in the hypothalamus, triggering dopamine release in reward circuits and oxytocin stimulation in the paraventricular nucleus. This produces the subjective experience of wanting, the appetitive drive that precedes and enables the entire sexual response cycle. The discovery was serendipitous. Researchers studying Melanotan II for tanning found subjects reporting spontaneous arousal. PT-141 was optimized from that observation. A dermatology project became the first centrally acting pharmacotherapy for sexual desire.

Desire activation operates at the neurological level. PT-141 addresses the motivation to want, not the mechanical ability to perform. This makes it effective for both men and women and complementary to (not redundant with) PDE5 inhibitors like sildenafil. On-demand dosing allows use 45 minutes to 2 hours before anticipated activity. Effects can last 6-12 hours. No daily regimen required. No hormonal manipulation. The melanocortin signal fires and the wanting follows.

Administer via subcutaneous injection using a 27-31 gauge insulin syringe. Inject into the abdomen or upper thigh approximately 45 minutes before anticipated use. Your prescribing provider will determine appropriate dosing. PT-141 should not be used more than once in 24 hours or more than 8 times per month. Store refrigerated at 36 to 46 degrees Fahrenheit. Protect from light.

Nausea occurs in approximately 40% of patients, typically at the initial dose, and diminishes with subsequent use. Flushing affects approximately 20%. Headache and injection site reactions are reported at lower rates. PT-141 may transiently increase blood pressure. A darkening of skin or gum pigmentation has been observed with repeated dosing.

Disclaimer and Transparency

Important Information About Compounded Injectables

Compounded medications are not reviewed or approved by the FDA and do not undergo the same pre-market evaluation as FDA-approved drugs.
IVUSE peptide injections are prepared using peptide ingredients by FDA-registered, U.S.-licensed 503A & 503B compounding pharmacies, where available and clinically appropriate.
Availability and formulation may vary based on state regulations, evolving clinical guidance, and pharmacy partners.

All prescriptions, treatment decisions, and care plans are made independently by licensed healthcare providers using their professional judgment. Images and product depictions are for illustration only; actual packaging and supplies may vary.

*If you are interested in a prescription product, IVUSE will coordinate a telehealth visit with a licensed medical provider who will determine whether you are an appropriate candidate based on your health profile and current standards of care. If approved, a prescription will be issued and filled by one of our partner pharmacies. All prescriptions are subject to provider discretion and clinical appropriateness.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. All information provided here is for educational purposes only and does not replace personalized medical advice from a qualified healthcare professional.

Stop the medication and contact your provider if you experience persistent or concerning symptoms. Seek immediate medical care if you develop signs of a severe allergic reaction (such as hives, facial swelling, or difficulty breathing) or any rapidly worsening symptom.